biotech
Genentech Licenses BioInvent's Cardiovascular Drug Candidate
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on January 15, 2007
Genentech Licenses BioInvent's Cardiovascular Drug Candidate
Genentech, Inc. is paying an upfront payment of $15 million to co-develop and commercialize BioInvent´s proprietary antibody candidate, BI-204, for the potential treatment of multiple cardiovascular conditions. In addition, BioInvent could receive further milestone payments of up to $175 million as well as royalties on sales in North America.

BI-204 is developed to prevent atherosclerosis and myocardial infarction by blocking a major mediator of vascular inflammation that is believed to lead to the formation of unstable plaque in the vessel wall.

Source: BioInvent



Permalink: Genentech Licenses BioInvent's Cardiovascular Drug Candidate
Tags: cardiovascular+disease  athersclerosis  myocardial+infarct  Genentech  BioInvent  biotech  drug+candidate 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/49322
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Genentech Licenses BioInvent's Cardiovascular Drug Candidate:

  • Currently 9.25/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.25 out of 4 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!